Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery

• Status: Withdrawn
• Trial end date: 2022-02-28
• Target enrollment: 0
• Participant gender: All

Summary

Currently, there are no studies that address the optimum dosage of lidocaine for surgical procedures. Lidocaine is a local anesthetic that is injected to induce anesthesia. Improper or inefficient pain treatment can lead to longer hospital stay, and adverse side effects such as nausea and vomiting. Opioids are the primary drug to treat moderate to severe pain, but are also responsible for nausea and other side effects. Lidocaine has shown to have opioid sparing effects; meaning less opioid use is necessary for pain relief. In this study, we will conduct a clinical trial to assess the difference between different lidocaine dosage schedules to determine the optimum dosage that brings maximum pain relief while minimizing adverse side effects and patient stay. A large benefit in using lidocaine is its documented opioid sparing which allows for minimal drug treatment.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McMaster University
• Collaborator: St. Joseph's Healthcare Hamilton
• Treatments: Lidocaine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Bariatric patients 18 years or older undergoing major bowel surgery

• Patient capable to complete informed consent

Exclusion Criteria:

• Pediatric population

• Inability to complete informed consent

• Patient refusal

• Chronic aspirin or NSAID intake

• Known allergy to aspirin and/or NSAIDs, or lidocaine

• History of bronchial asthma requiring intubation

• Peptic ulceration

• Coagulopathy

• Renal insufficiency

• Opioid abuse

• Pregnancy

• Conversion from laparoscopic to open surgery.

• Other relative contraindications for lidocaine; unstable CAD, Recent MI, Heart Failure, Heart Block, Electrolyte Disturbances, Liver Disease, Cardiac Dysrhythmias, and Seizure Disorders.